METTL3 and neoplasm: The tumor inhibition rate of everolimus in METTL3-high tumors was significantly higher than that in control tumors (89.92% vs. 73.26%, P = 0.0465, Fig. 8c–e), suggesting that METTL3-high tumors could be inhibited by everolimus more effectively.